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44 Background There is no gold standard treatment of motor functional neurological disorder (mFND) 
45 and limited evidence exists on the effectiveness of cognitive behavioural therapy (CBT) in treating the 
46 disorder. CBT is effective in the treatment of other somatoform disorders. 
47 Aim To evaluate demographic and clinical characteristics, treatment outcomes, and treatment 
48 dropout of mFND patients who received CBT in a neuropsychiatric outpatient clinic. 
49 Methods We used a large anonymised psychiatric register to assess all patients receiving outpatient 
50 CBT in a neuropsychiatry clinic between 2006 and 2016. We assessed socio-demographic variables, 
51 physical symptom improvement and changes in clinical outcome and mood scores. We compared 
52 outcomes to a control group of patients with organic diseases treated with CBT in the same clinic.  
53 Results We identified 98 patients with mFND and 76 controls with organic neuropsychiatric disease 
54 (ONP). mFND patients were more likely to have experienced childhood sexual abuse (23.8% v 8.2%, 
55 χ2: 7.3, p = 0.01). A logistic regression analysis found no socio-demographic differences between mFND 
56 patients who dropped out early versus treatment completers. Both mFND and ONP patients showed 
57 significant improvements in overall CORE-OM, HONOS-ABI and PHQ-9 scores. A logistic regression 
58 analysis in the mFND group found that an acceptance of psychological explanations prior to treatment 
59 significantly predicted symptom improvement. 
60 Conclusions mFND patients treated in a specialist CBT clinic show similar improvements in physical 
61 and psychological functioning to ONP patients. A future RCT would help establish the specific elements 








67 Functional neurological disorder with motor symptoms (mFND) refers to a spectrum of neurological 
68 symptoms which are not explained by standard neurological disease {1}.  The disorder comprises a 
69 wide range of symptoms including weakness, numbness, tremor through to gait disorders and 
70 paralysis. 
71 There is no gold standard treatment and the development of manualised treatments has been 
72 hindered by a lack of consensus on the definitions, classification and diagnosis of the disorder. 
73 Randomised controlled trials (RCTs) of physiotherapy within a biopsychosocial framework for mFND 
74 show promising results {2-5} and there is evidence from smaller studies and case series that a multi-
75 disciplinary rehabilitative approach is effective {6-9}.  
76 Cognitive behavioural therapy (CBT) is one element of the multi-disciplinary approach and emphasises 
77 the importance of cognition and behaviour in maintaining the disorder. Maladaptive cognitions, such 
78 as dysfunctional automatic thoughts, somatic misinterpretations and illness beliefs are challenged in 
79 a bid to modify behaviour {10}. Techniques like muscle relaxation, psychoeducation, grounding 
80 techniques, problem-solving exercises and behavioural experiments may be employed to help disrupt 
81 maladaptive patterns of symptom formation and maintenance. 
82 Evidence on the effectiveness of CBT in treating mFND is limited. A case study reported benefits up to 
83 a year for a patient with a functional dystonia after 12 CBT sessions {11}. A small pilot study reported 
84 improvements after CBT and adjunctive physical therapy compared to standard medical care {12}. In 
85 trials of CBT in other forms of FND, a number of studies show improvements in patients with non-
86 epileptic seizures {13-15} and there is good evidence of its effectiveness in other somatoform 
87 disorders {16-23}, although one RCT comparing CBT to GP care found no significant difference {24}. 
88 This evidence lends support to an a priori assumption that CBT will improve mFND symptoms although 
89 such treatment may pose challenges in practice as patients may be resistant to psychological accounts 
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90 of symptoms, which could affect its uptake and effectiveness. No previous RCTs have however tested 
91 the effectiveness of CBT for mFND. 
92 The aim of this study was to evaluate the outcomes of mFND patients who received a course of CBT 
93 at an outpatient neuropsychiatry clinic in South London and Maudsley (SLaM) NHS Foundation Trust. 
94 Since this is an observational study based on clinical practice within a single mental health NHS trust 
95 – albeit one which offers specialist services in neuropsychiatry - we included a comparison group. We 
96 did this to control for the potential non-specific effects of treatment and general improvements in any 
97 group of patients with mental health problems over time. Our control group comprised patients 
98 treated with CBT by the same clinical team for the neuropsychiatric and behavioural manifestations 
99 of organic conditions. We compare socio-demographic characteristics, treatment dropout and clinical 
100 outcomes. We hoped to establish evidence that might help inform a future RCT for CBT for mFND.
101 Method
102 Design and source of clinical data
103 This was a retrospective case-control comparison of mFND and ONP patients treated in a 
104 neuropsychiatry outpatient clinic in SLaM between 1st January 2006 and 31st December 2016. Data 
105 were obtained from the SLaM Biomedical Research Centre’s (BRC) ‘Clinical Records Interactive Search’ 
106 (CRIS) database. CRIS holds records on over 250,000 anonymised individuals referred to SLaM services 
107 {25}. This is a single online system where all patient information, medication, diagnoses, 
108 correspondence, and clinical outcome scores are recorded. Records can be retrieved using search 
109 terms of the database’s structured fields such as age, gender and diagnosis or searches of free text 
110 clinical notes and correspondence. 
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111 Study setting and participants
112 The outpatient neuropsychiatry services at SLaM assess and treat psychological complications 
113 associated with neurological disorders and functional and dissociative disorders. Patients receiving a 
114 CBT referral are offered a comprehensive assessment after which they may be recommended a formal 
115 CBT course. A common treatment course is 12-15 sessions, usually occurring weekly. 
116 Cases included all patients aged over-18 with a primary or secondary diagnosis of ‘Conversion disorder 
117 with motor symptom or deficit’ (ICD-10 code: F44.4) or those without a formal F44.4 diagnosis but 
118 whose notes indicated they received treatment for functional motor or movement symptoms. 
119 Control group patients were included if they were over-18, were being treated in the same CBT clinic 
120 for psychiatric and behavioural manifestations of an organic disease and had no evidence of functional 
121 symptoms. Controls were excluded if they received treatment for non-epileptic seizures only. 
122 Patients in either group were excluded from the study if they had had a CBT assessment but their 
123 treatment had not begun but were included if CBT had begun but the course was not yet complete. 
124 Ethical approval
125 The CRIS database received ethical approval from the Oxfordshire Research Ethics Committee 
126 (08/H0606/71+5) as an anonymised dataset for mental health research. Ethical approval as an 
127 anonymised database for secondary analysis was granted in 2008, and renewed for a further five years 
128 in 2013. This project was approved by a patient-led oversight committee on 12th May 2016.
129 Outcome measures
130 We extracted information on year of birth, gender, ethnicity, marital status, employment, housing 
131 status, receipt of benefits, use of walking aids, having a carer or being a carer, physical comorbidity, 
132 lifetime experience of sexual or physical abuse, age at symptom onset and CBT assessment, and 
133 acceptance of psychological formulations before and after CBT. 
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134 CBT attendance was calculated as the number of sessions attended out of the total number of sessions 
135 offered. If there was a discrepancy between figures, the reason was recorded. Information on 
136 treatment dropout was recorded. 
137 We created a three-point scale to measure patient improvement classified as symptoms ‘improved’, 
138 ‘remained the same’, or ‘got worse’. ONP patients’ improvements were based on the goal set by the 
139 patient and therapist at the start of therapy.
140 We collected Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM), Health of the 
141 Nation-Acquired Brain Injury (HoNOS-ABI) and Patient Health Questionnaire (PHQ-9) scores. Pre-CBT 
142 scores were classified as occurring nearest patients’ CBT assessment date and post-CBT scores were 
143 those taken nearest to the final CBT treatment session or follow-up session. Scores were included if 
144 they were measured within 180 days before or after the date in question.  
145 Statistical analysis
146 We used means, standard deviations (SDs), and frequency data to assess differences between mFND 
147 and ONP groups. Chi-square analyses were used for frequency data and Mann-Whitney U calculations 
148 for non-normally distributed score comparisons. Proportions were used to describe categorical data. 
149 An exact McNemar’s test was used to determine the change in proportion of mFND patients accepting 
150 psychological formulations before and after CBT. A repeated-measures ANOVA was conducted to 
151 assess the change in CORE-OM scores and their associations with socio-demographic variables. We 
152 conducted a binary logistic regression analysis to assess the socio-demographic variables associated 
153 with symptom improvement in mFND patients. SPSS for Windows (SPSS v21.0, Chicago, Illinois, USA), 
154 Microsoft Excel (Microsoft Office Professional Plus 2010, Version 14.0.7015.1000) and GraphPad Prism 
155 (Version 5.01, GraphPad Software, La Jolla California USA) were employed in the analysis.




157 Patient characteristics 
158 Our search returned 941 patients, of whom 573 were functional patients with no evidence of motor 
159 symptoms and a further 21 who did not meet other study criteria (e.g. aged under-18). A further 102 
160 mFND patients and 71 ONP patients were excluded as they had not yet commenced treatment. The 
161 most common reasons for non-commencement of treatment in mFND patients was due to acceptance 
162 of a referral to the Trust’s inpatient neuropsychiatry ward (36.3%, versus 19.7% in the ONP group, χ2 
163 = 5.5, 95% CI: 2.1 – 30, p < 0.05), non-attendance at assessment or treatment appointments (19% of 
164 mFND versus 26.8% of ONP patients, χ2 = 1.6, 95% CI: -4.2 - 21, p > 0.05), and refusal to commence 
165 treatment (13.7% of mFND versus 2.8% of ONP patients, χ2 = 5.9, 95% CI: 2.2 – 19.2, p < 0.02).
166 98 mFND and 76 ONP patients began CBT and form our study’s sample. Amongst ONPs, epilepsy was 
167 the most common disease (46.1%), followed by Tourette’s syndrome (16.9%), sleep disorders (6.7%), 
168 multiple sclerosis (5.6%) and other neurological diseases (20.2%). We assessed lifetime prevalence of 
169 fatigue, anxiety and depression (including low mood, suicidal thoughts and ideation) in ONP patients. 
170 Fatigue affected 55.4%, depression affected 88.2%, and a history of anxiety was recorded in 91.8% of 
171 patients. 
172 mFND patients were more likely to be female (72.4% v. 44.7%, χ2: 13.6, 95% CI: 12.2 – 41.9, p = 0.001), 
173 unemployed (52.6% versus 35.5%, χ2: 5, 95% CI: 2.2 – 30.8, p = 0.03), to have a carer (27.6% versus 
174 14.3%, χ2: 4.4, 95% CI: 0.9 – 24.7, p = 0.04) and to have experienced childhood sexual abuse compared 
175 to ONP patients (23.8% versus 8.2%, χ2: 7.3, 95% CI: 4.5 – 25.9, p = 0.007). 
176 At analysis, the average age of mFND patients was 44.5 years (SD: 12) and the mean age of 
177 psychological symptom onset was 30 years (SD: 14). mFND patients received their CBT assessment on 
178 average at 40.3 years of age (SD: 13) (see Table 1).
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179 The most common mFND symptom was weakness (26.9%), most frequently in the leg or entire body. 
180 After weakness, pain was frequently reported (26.3%), followed by tremor, shakes, jerking or dystonia 
181 (24.6%). The area of the body most frequently affected by motor symptoms was the leg (15.4%), 
182 followed by unilateral and bilateral bodily regions (14.3% respectively), arms (11.4%) and back and 
183 chest regions (11.4%).  All patients had at least one motor symptom, with 83.7% of patients 
184 experiencing two motor symptoms, 41% with three and 12.2% reporting four. 
185 Openness to a psychological formulation
186 Prior to therapy commencement, 49% of mFND patients accepted a psychological formulation of their 
187 symptoms, 27.6% did not, and 13.3% were unsure. In ten cases, no information was available or a 
188 psychological account was not applicable. 
189 After therapy, 71.6% accepted a psychological account, 17.9% did not, and 5.3% were unsure. There 
190 was a significant increase in the proportion of patients accepting a psychological account after CBT 
191 (McNemar’s test, p = 0.004).  
192 Treatment attendance 
193 56.1% of mFND and 56.6% of ONP patients attended all CBT sessions offered, 28.6% of mFND and 
194 26.3% of ONP patients dropped out early, 6.1% of mFND and 2.6% of control patients’ therapists 
195 decided to stop treatment early, while 9.2% mFND and 14.5% of control patients were still receiving 
196 therapy at the time of data collection. 
197 We compared the socio-demographic characteristics of mFND patients who dropped out of therapy 
198 early to those who attended all offered sessions. There were no statistical differences in age, gender, 
199 marital status, ethnicity, employment, abuse experience, acceptance of psychological explanations, 
200 wheelchair usage or treatment outcome scores. 




202 In total, 49.4% mFND patients and 58% ONP patient showed symptomatic improvement, a non-
203 significant difference. 37.8% of mFND and 20.4% of ONP patients’ symptoms remained the same after 
204 CBT, while 8.2% of mFND and 11.8% of ONP patients’ symptoms worsened. 
205 We compared the difference in socio-demographics between mFND patients whose symptoms 
206 improved to mFND patients whose symptoms stayed the same or got worse. In the unadjusted 
207 analysis, patients who were employed (OR: 2.5, 95% CI: 1 – 6.2, p = 0.05), who currently or had 
208 previously worked as health and social care workers (OR: 3.1, 95% CI: 1.1 – 9, p < 0.05), and patients 
209 who accepted a psychological formulation before therapy (OR: 4.6, 95% CI: 1.5 – 13.9, p < 0.05) were 
210 more likely to improve. Those in receipt of benefits (OR: 0.2, 95% CI: 0.09 – 0.6, p < 0.05), and patients 
211 using a wheelchair or walking aid (OR: 0.3, 95% CI: 0.14 – 0.8, p < 0.05) were more likely to get worse 
212 or stay the same. There were no differences in age at CBT assessment or age of psychological symptom 
213 onset between those who improved and the rest. Table 2 outlines these results.
214 Using a logistic regression model to adjust for potentially confounding variables, the only significant 
215 predictor of improvement was acceptance of a psychological formulation before therapy (OR: 36.7, 
216 95% CI: 2.1 – 627, p < 0.02). The model explained 63% (Nagelkerke R2) of the variance in symptom 
217 improvement and correctly classified 50% of cases (see Table 2). 
218 24 mFND patients had pre- and post-therapy CORE-OM scores. mFND patients’ mean global CORE-
219 OM score dropped from a mean of 15.5 (SD: 6.2) (clinically moderate) at baseline to a clinically low 
220 mean of 10 (SD: 6.6) (t = 3.9, df = 23, 95% CI: 2.6 – 8.3, two-tailed p = 0.001). ONP patients’ scores also 
221 dropped significantly from a mean of 16.3 (SD: 6.8) (moderate) to 12.8 (SD: 6.6) (clinically mild) (t = 
222 2.9, df = 23, 95% CI: 1.06 – 5.9, two-tailed p =0.007). 
223 We conducted a repeated-measures (pre-CBT versus post-CBT) ANOVA, with patient group (mFND 
224 versus ONP) as a fixed factor. The Bonferroni-corrected interaction between the mFND and ONP 
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225 groups and the change over time (pre- versus post-CBT) was not statistically significant (F1,46 = 1.13, p 
226 = 0.30, partial η2 = 0.02). 
227 HoNOS-ABI scores were available for 22 mFMD and 15 ONP patients. HoNOS-ABI scores range from 0 
228 to 48 (most severe). Following CBT, the mFND mean HoNOS-ABI score dropped from 11.5 (SD: 6) to 
229 7.3 (SD: 5), a significant change (Z = -3.1, p = 0.002). In ONP patients, the mean dropped significantly 
230 from 12.3 (SD: 7) to 6.5 (SD: 4, Z = -3, p = 0.003). A two-way repeated measures ANOVA found no 
231 significant difference between the groups’ changes in pre- and post-therapy HoNOS-ABI scores (F1,35 
232 = 0.58, p = 0.45, partial η2 = 0.02). 
233 PHQ-9 data were available for 16 mFND patients and ten ONP control patients. Post-CBT, there was a 
234 statistically significant drop in mFND patients’ scores from 13.5 (SD: 7) to 9.9 (SD: 6, t = 2.6, df = 15, 
235 95% CI: 0.6 – 6.5, two-tailed p = 0.02). Using a repeated-measures two-way ANOVA, the interaction 
236 between the mFND and ONP groups and the change over time between the pre-and post-CBT 
237 assessment was not statistically significant (F1,24 = 0.22, p = 0.64, partial η2 = 0.01). Figure 1 summarises 
238 both group’s pre- and post-CBT scores on all measures.
239 For all three measures, we compared the socio-demographics of mFND patients with available scores 
240 to mFND patients with none available. No significant differences emerged. 
241 Discussion
242 The results of this study suggest that outpatient CBT treatment for mFND has positive effects on motor 
243 symptoms, distress, depression, general health and social functioning. Half the group saw 
244 improvements in their physical symptoms and only a small proportion of mFND patients’ symptoms 
245 got worse (8.2%).  
246 We evaluated whether specific characteristics contribute to symptom improvement. Previous positive 
247 prognostic factors in FND include being married {26, 27} and younger age of onset {28, 29}. One study 
248 found females more likely to recover {3}, but this has not be found elsewhere {26, 30-32}. We found 
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249 no effect of gender, ethnicity, marital status, sexual abuse or age at symptom onset on symptom 
250 improvement. However, the long delay we observed between onset and the offer of treatment is a 
251 general concern for NHS services. 
252 Our regression analysis revealed a strongly predictive variable in symptom improvement: acceptance 
253 of psychological accounts of symptoms prior to CBT onset, corroborating previous literature {27, 33, 
254 34}. By ‘psychological’, we do not mean psychodynamic, rather an information processing account 
255 invoking attentional processes, attribution errors and behavioural avoidance as well as appreciating 
256 temporal relationships between symptoms and ‘stress’, mood, anxiety or dissociation. It is possible 
257 that where patients do not accept a psychological formulation prior to therapy, CBT therapists may 
258 invest more time in explaining this perspective, patients may be less likely to utilise therapeutic tools 
259 within and outside the clinic and it may be more challenging to build a therapeutic alliance.  
260 While symptom severity might independently explain symptom improvement and patients’ 
261 acceptance of a psychological formulation prior to CBT, in our analysis, we used patients’ walking aid 
262 usage as a symptom severity proxy and the predictive significance of pre-CBT psychological 
263 acceptance remained.
264 While pre-CBT acceptance of psychological explanations predicts patient improvement, in this study 
265 three mFND patients did not accept this explanation after CBT but nonetheless experienced 
266 symptomatic improvements. Saifee et al. (2012) argue that patients’ psychological attributions could 
267 be used as a CBT selection criterion. Our findings suggests that, albeit in a small proportion of patients, 
268 improvement may be possible regardless of attribution {34}. 
269 That only half the mFND group experienced physical symptom improvements might appear low, but 
270 previous literature indicates FND prognosis is poor. A systematic review found 39% of mFND patients 
271 had the same or worse symptoms at follow-up, and only 20% had complete remission {35}. Of these 
272 studies, some included patients who received heterogeneous treatments and of those, 49% were the 
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273 same or worse. One study reported results from an RCT testing CBT on patients with medically 
274 unexplained symptoms and at 12-month follow-up, 51% of patients maintained improvement, a  
275 finding comparable to our own {16}. 
276 The goals of CBT in functional disorders may not always be the immediate reduction of physical 
277 symptoms but rather improvements in cognitions and behaviours associated with symptoms. Patients’ 
278 goals are commonly discussed and agreed at the start of therapy. Had our symptom score derived 
279 purely from the goals set at the start of therapy, it is possible a higher proportion of patients would 
280 have been classed as ‘improved’. Our use of routine medical records necessarily limits the type and 
281 range of measures we could employ. 
282 The psychometric measures we collected showed significant improvements for both groups. The 
283 HoNOS-ABI is clinician-rated, and it is possible clinicians give more favourable scores at the end of 
284 treatment, due to bias. Most services however implement quality control measures such as 
285 independent assessors to help reduce such inflation of scores. Importantly, the CORE-OM and PHQ-9 
286 are self-report scales so are not subject to clinician bias. In our sample, a minority of patients in both 
287 groups had a complete set of pre- and post-treatment scores which may represent a biased sample. 
288 To account for this, we compared the socio-demographic differences between mFND patients who 
289 had pre- and post-CBT scores for each on all three outcome measures to those with a pre- or post-CBT 
290 score only or neither. No differences emerged. We conducted a further analysis, not reported here, 
291 assessing pre- and post-CBT scores according to the treating clinician, and found no differences. 
292 There are several weaknesses inherent in this observational study. The observed improvement in 
293 measures may be explained by a placebo effect, a regression to the mean phenomenon, or other 
294 factors that were not measured, such as medication. Our findings do however suggest that response 
295 to CBT in functional patients is at least as good as that of patients with organic disease and significant 
296 psychological co-morbidities referred to the same service. In fact, the results in our control group 
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297 make a unique contribution to the literature on the range of disorders responsive to a tailored CBT 
298 intervention.  
299 The numbers in our study are relatively small and our use of a medical register means any data errors 
300 cannot be corrected. We could not blind the data collector so we cannot rule out the possibility of 
301 observer bias on free-text information. This study comprised patients who are severe enough to 
302 require psychotherapy, but who are willing to accept such a referral. Patients who express overt 
303 opposition to psychological explanations will be less likely to be offered therapy and will not be 
304 represented here. The national referral status of the clinic may mean patients offered weekly 
305 appointments who live further from the clinic are not represented, a specific concern in this patient 
306 group with chronic motor deficits. In addition, we do not know whether the observed improvements 
307 were sustained over a longer period. 
308 Finally, unlike a traditional RCT, clinicians were not following a treatment manual, and each patient in 
309 this study received a course of CBT tailored to their own needs. Our naturalistic results do not however 
310 have the imposition of strict selection criteria which can limit generalisability. Instead this study offers 
311 useful information on the practicalities of delivering CBT in the NHS. Most RCTs in FND do not describe 
312 why patients refuse treatment and our results are the first to provide such information, findings 
313 potentially pertinent to future service planning. Most importantly, we can reject the therapeutic 
314 nihilism sometimes associated with FND. 
315 A future RCT with extensive follow-up would help confirm (or refute) our preliminary results, account 
316 for the placebo effect, establish which elements of CBT are most effective, which patients are most 
317 likely to respond to treatment and how long patients might expect to benefit after therapy cessation.
318
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437 Figure 1: Line graphs demonstrating change in mean CORE-OM, HoNOS0ABI and PHQ-9 scores 
438 between mFND and ONP groups pre- and post-CBT
439
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441 Table 1: Table showing the socio-demographic characteristics of mFND and ONP control patients
442 Table 2: Logistic regression model assessing the relationship in socio-economic factors and patients’ 
















456 Table 3 Table showing the socio-demographic characteristics of mFND and ONP control patients
mFND ONP




Female 71 72.4 34 44.7 13.6 12.2 – 41.9 0.001
Male 27 27.6 42 55.3
Ethnicity
British 66 67.3 54 71.1 0.3 -10.9 – 18 0.60
Any white background/any other 
ethnicity
15 15.3 11 14.5 0.02 -10.4 – 11.3 0.88
Any other black/Asian/African/
Caribbean/Indian background1
17 17.3 11 14.5 0.24 -8.7 – 13.5 0.61
Marital status
Single 42 42.9 44 57.9 3.8 - 0.8 – 30 0.051
Married/civil partner/cohabiting 45 45.9 27 35.5 1.9 -4.3 – 24.3 0.17




11 11.2 8 10.5 0.02 -9.4 – 10 0.88
Living with family 20 25.6 12 19 0.86 -8.4 – 20.8 0.35
Privately owned/privately rented 47 60.3 43 68.3 0.96 -7.9 – 23 0.33
Employment
Employed 33 34 37 48.7 3.8 -0.8 – 29.7 0.051
Unemployed 51 52.6 27 35.5 5 2.2 – 30.8 0.03
Other2 14 14.3 12 15.8 0.08 -9 – 12.8 0.78
Receives benefits 36 39.6 25 35.7 0.25 -12.1 – 19.4 0.61
Is a health or social care worker 20 21.3 11 14.9 1.1 -6.4 – 18.5 0.29
Has a carer 24 27.6 10 14.3 4.4 0.9 – 24.7 0.04
Physical health condition present 76 79.2 76 79.2 0.30 -9 – 16 0.62
Abuse 
History of child sexual abuse 19 23.8 5 8.2 7.3 4.5 – 25.9 0.007
History of child physical abuse 23 28.4 13 21 1.2 -5.7 – 19.7 0.27
History of adult SA or PA 19 23.8 19 16.1 1.6 -4.6 – 19.1 0.21
History of family mental health problems 51 63.8 51 63.8 0.009 -13.6 – 14.6 0.92
Mean age3 SD SD
Age at analysis 44.5 12 45.4 13 1.3 -1.4 – 7.4 0.19
Age at symptom onset 30 14 27.8 15 3105.5 0.27
Age at CBT assessment 40.3 13 40.7 13 3669 0.87
CBT attendance n % N %
Attended all sessions 55 56.1 43 56.6 0.004 -15-15.9 0.95
Dropped out early 28 28.6 20 26.3 0.11 -12 – 16.1 0.74
Therapist stopped sessions/sessions 
on-going
15 15.3 13 17.1 0.1 -9 – 13.4 0.75
1Includes proportion of patients where ethnicity was not know
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463 Table 4 Logistic regression model assessing the relationship in socio-economic factors and patients’ 







Socio-demographics n % n %
Un-
adjusted 
OR 95% CI p value
Adjusted 
OR1 95% CI p value
Total 44 49.4 45 50.6
Gender Female 32 72.7 33 73.3 0.97 0.4 – 2.5 0.95 0.34 0.02 – 5.2 0.44
Male 12 27.3 12 26.7
Ethnicity British 32 72.7 28 62.2 1.6 0.7 – 4 0.30 0.20 0.01 – 3.0 0.24
Other ethnicity 12 27.3 17 37.8
Single, divorced, widowed or 
separated
24 54.5 24 53.3 1.05 0.5 – 2.4 0.91 1.7 0.1 – 25.2 0.72Marital 
status
Married, civil partner or cohabiting 20 45.5 21 46.7
Work Employed 20 45.5 11 25 2.5 1 – 6.2 0.05 1 0.4 -23 1
Unemployed, retired or sick leave 24 54.5 33 75
Health/social care worker 14 33.3 6 14 3.1 1.1 – 9 0.04 21.1 0.3 - 1596 0.17
Not a health/social care worker 28 66.7 37 86
Carer Patient is a family carer 5 11.9 5 11.9 1 0.3 – 3.7 1.0 0.06 0.01 – 5.6 0.22
Patient is not a family carer 37 88.1 37 88.1
Patient has a carer 8 20 13 33.3 0.5 0.2 – 1.4 0.18 0.15 0.01 – 2.5 0.19
Patient doesn’t have a carer 32 80 26 66.7
Benefits Receives benefits 9 22 24 44.2 0.2 0.09 – 0.6 0.002 0.22 0.01 – 7.2 0.40
Does not receive benefits 32 78 19 55.8
Disability Uses wheelchair or walking aid 15 36.6 26 63.4 0.3 0.14 – 0.8 0.02 0.94 0.1 – 10 0.96
Doesn’t use wheelchair 26 63.4 15 36.6
Accepted psych factors before 
therapy
26 81.3 17 48.6 4.6 1.5 – 13.9 0.007 36.7 2.1 – 627 0.02Psych 
factors
Didn’t accept psych factors before 
therapy
6 18.8 18 51.4
Abuse Experienced CSA 8 23.5 8 20.5 1.2 0.4 – 3.6 0.76 4.2 0.1 – 135 0.41
Didn’t experience CSA 26 76.5 31 79.5
Experienced CPA 13 63.9 8 20.5 2.2 0.8 – 6.2 0.14 14.5 0.36 – 592 0.16
Didn’t experience CPA 23 36.1 31 79.5
*Eight mFND patients got worse and nine control patients got worse
1 Independent samples t-test
1Adjusted for gender, age of psychiatric symptom onset, ethnicity, marital status, employment, marital status, employment, social care worker 
status, whether patient has a carer, whether patient is a carer, receipt of welfare benefits, current wheelchair use, acceptance of psychological 
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Figure 1 Line graphs demonstrating change in mean CORE-OM (mFND n =24; ONP n = 24), HoNOS-ABI (mFND n = 22, 
ONP n = 15) and PHQ-9 scores (mFND n = 16, ONP n = 10) between mFND and ONP groups pre- and post-CBT
CORE-OM scores range from 0-40: Healthy (0-5); low level (5-10); mild (10-15); moderate (15-20); moderate-to-severe 
(20-25); severe (25 -40)
HoNOS-ABI scores range from 0 to 48 (most severe)
PHQ-9 scoring guide: ‘0-4’ no depression; ‘5-9’ mild; ‘10-14’ moderate; ‘15-19’ moderately severe; and ‘20-27’ severe
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